Abiopharma

It is approved by the FDA for the treatment of certain patients with ES and certain patients with FL under FDA accelerated approval granted in January and June 2020, respectively. Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said The approval of TAZVERIK in the Hainan Pilot Zone allows patients to gain early access to this first-in-class EZH2 inhibitor in China, as part of. 1 2 hcm-20220601ex9914e1cfa.